Insurance coverage varies by plan and the condition being treated
Medicare currently limits its coverage of GLP-1s to individuals with Type 2 diabetes or certain heart conditions, excluding prescriptions aimed solely at obesity
Liraglutide: The First Generic GLP-1 The FDA approved and Teva launched a generic version of Saxenda, making it the first generic GLP1 indicated specifically for weight loss in the U.S
Retatrutides multi-pathway approach means it doesnt just target GLP-1, like semaglutide, but targets GIP and glucagon, which could boost both appetite control and energy expenditure
Activity of pramlintide, rat and human amylin but not A1-42 at human amylin receptors
The nausea, digestive discomfort and fatigue that many people experience in the early weeks of treatment often return, usually in a milder form, when the dose increases